Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Peter Leidenmühler"'
Autor:
Peter Leidenmühler, Joris Höfinghoff, Norbert Haider, Gerald Brachtl, Markus Weiller, Ivan Bilic, Bagirath Gangadharan
Publikováno v:
Drug Delivery and Translational Research.
Immunoglobulin replacement therapy is a life-saving treatment in patients with immunodeficiency and effective in the management of autoimmune disorders. Immunoglobulins are administered intravenously or subcutaneously, with the latter route reducing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7390fed003f0256a53277f98f9fb08af
https://doi.org/10.1007/s13346-023-01321-y
https://doi.org/10.1007/s13346-023-01321-y
Autor:
Werner Höllriegl, Bernhard Majer, Peter Leidenmühler, Paolo Rossato, Maria Schuster, Friedrich Scheiflinger, Alexandra Kopic, Tanja Ruthsatz, Helmut Glantschnig
Publikováno v:
Blood Coagulation & Fibrinolysis
Insufficiency of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motif repeats-13) is the cause of thrombotic thrombocytopenic purpura (TTP) and contributes in microangiopathy in sickle cell disease (SCD). Recombinant ADAMTS13 effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5cefee680fde41cfc7bc4ee7531776
https://pubmed.ncbi.nlm.nih.gov/34267062
https://pubmed.ncbi.nlm.nih.gov/34267062
Autor:
Alexandra Kopic, Tanja Ruthsatz, Hanspeter Rottensteiner, Frank M. Horling, Friedrich Scheiflinger, Werner Höllriegl, Alexander Bauer, Gerald Schrenk, Peter Leidenmühler, Martin J. Wolfsegger, Gerald Höbarth, Alfred Weber, Herbert Gritsch, Birgit M. Reipert, Helmut Glantschnig, Karima Benamara, Veronika Ehrlich, Michael Dockal, Maria Schuster, Peter Turecek
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 371:95-105
Extended half-life (EHL) factor therapies are needed to reduce the burden of prophylaxis and improve treatment adherence in patients with hemophilia. BAX 826 is a novel polysialylated full-length recombinant factor VIII [polysialyic acid (PSA) rFVIII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da9442072f9ea3b0be9b7fc5c70e52a0
https://doi.org/10.1124/jpet.119.260067
https://doi.org/10.1124/jpet.119.260067
Autor:
Maria Schuster, Helmut Glantschnig, Werner Höllriegl, Alexandra Kopić, Alexander Bauer, Peter Leidenmühler, Karima Benamara
Publikováno v:
Laboratory Animals
Genetically engineered mouse models are used to investigate beneficial treatment in haemophilia by comparison with wild-type mice. It has been recognized that wild-type and haemophilic mice of different genetic backgrounds show different bleeding phe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf82f73a650b6ab594bb39c69857f83
https://doi.org/10.1177/0023677218811059
https://doi.org/10.1177/0023677218811059